{
    "clinical_study": {
        "@rank": "80516", 
        "acronym": "ALLIVE", 
        "arm_group": {
            "arm_group_label": "Patients with MDS and AML prior to allogeneic SCT"
        }, 
        "brief_summary": {
            "textblock": "The ALLIVE (ALLogeneic Iron inVEstigators) trial aims at quantifying the extent and dynamic\n      change of LPI occurrence during conditioning and at identifying LPI-predictive\n      peri-transplant parameters. Further points of interest are the improvement of systemic iron\n      overload (SIO) diagnostics and the correlation of different SIO parameters with outcome\n      after transplantation. The results of this trial will help to design prospective\n      interventional studies addressing therapeutic options in patients at risk for SIO-associated\n      toxicity during allogeneic stem-cell transplantation (allo-SCT)."
        }, 
        "brief_title": "Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "MDS and AML Prior to Allogeneic SCT", 
        "condition_browse": {
            "mesh_term": [
                "Myelodysplastic Syndromes", 
                "Preleukemia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >= 18 years at the time of signing the informed consent form\n\n          -  Signed informed consent\n\n          -  Diagnosis of AML or MDS according to WHO classification\n\n          -  Planned allogeneic stem cell transplantation after reduced intensity or myeloablative\n             conditioning from related or unrelated donors\n\n          -  At risk for iron toxicity as defined by ferritin >500 ng/ml and/or history of more\n             than 10 RBC transfusions prior to allo-SCT\n\n        Exclusion Criteria:\n\n          -  Claustrophobia or other mental disorders making MRI imaging unbearable for the\n             patient\n\n          -  Cardiac pacemakers, metal implants splinters or other contraindications for MRI\n\n          -  More than 1 Human leukocyte antigen (HLA) allele or antigen mismatch between donor\n             and recipient\n\n          -  Any condition, including the presence of laboratory abnormalities, which places the\n             subject at unacceptable risk if he/she were to participate in the study or confounds\n             the ability to interpret data from the study\n\n          -  Patients with a history of chronic drug abuse or another illness which does not allow\n             the patient to assess the nature and/or possible consequences of the study\n\n          -  Patients who are not likely to follow the trial protocol (lack of willingness to\n             cooperate)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Men and women with AML or MDS according to WHO classification."
            }
        }, 
        "enrollment": {
            "#text": "134", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01746147", 
            "org_study_id": "ALLIVE-2012"
        }, 
        "intervention": {
            "arm_group_label": "Patients with MDS and AML prior to allogeneic SCT", 
            "intervention_name": "No intervention and study treatment", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "MDS", 
            "AML", 
            "allogeneic SCT"
        ], 
        "lastchanged_date": "December 10, 2012", 
        "location": [
            {
                "contact": {
                    "email": "heike.weiss@umm.de", 
                    "last_name": "Stefan Klein, Dr.", 
                    "phone": "0621 - 383-4116"
                }, 
                "facility": {
                    "address": {
                        "city": "Mannheim", 
                        "country": "Germany", 
                        "state": "Baden-W\u00fcrttemberg", 
                        "zip": "68167"
                    }, 
                    "name": "III. Medizinischen Klinik H\u00e4matologie und Internistische Onkologie Universit\u00e4tsmedizin Mannheim"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "k.goetze@lrz.tu-muenchen.de", 
                    "last_name": "Katharina G\u00f6tze, Dr.", 
                    "phone": "089 - 4140-5618"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "state": "Bayern", 
                        "zip": "81675"
                    }, 
                    "name": "III. Medizinischen Klinik des Klinikums rechts der Isar"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dominik.wolf@ukb.uni-bonn.de", 
                    "last_name": "Dominik Wolf, Prof. Dr.", 
                    "phone": "0228 287 17233"
                }, 
                "facility": {
                    "address": {
                        "city": "Bonn", 
                        "country": "Germany", 
                        "state": "Nordrhein-Westfalen", 
                        "zip": "53127"
                    }, 
                    "name": "Medizinische Klinik und Poliklinik III Abteilung f\u00fcr H\u00e4matologie und Onkologie Universit\u00e4tsklinikum Bonn"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Martin.Wermke@uniklinikum-dresden.de", 
                    "last_name": "Martin Wermke, Dr", 
                    "phone": "0351 458-15624"
                }, 
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "state": "Saxony", 
                        "zip": "01307"
                    }, 
                    "name": "Universit\u00e4tsklinikum Carl Gustav Carus der TU Dresden Medizinische Klinik und Poliklinik I"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in MDS or AML Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial", 
        "overall_contact": {
            "email": "Claudia.Spielau@gwtonline.de", 
            "last_name": "Claudia Spielau, Dr.", 
            "phone": "0351 25933 123"
        }, 
        "overall_official": {
            "affiliation": "on behalf of GWT", 
            "last_name": "Martin Wemke, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Description of dynamic changes of LPI prior, during and after conditioning for allo-SCT using standard descriptive parameters (Mean or Median and appropriate confidence intervals)", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01746147"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "\u2022 Correlation coefficient of Liver iron concentration (LIC) and duration of detectable LPI during and after conditioning", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Area under the Receiver-Operator-Characteristic (ROC) as well as sensitivity and specificity of specific thresholds of serum ferritin and transfusion history for prediction of LIC", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Association of serum ferritin and LIC with hematopoietic cell transplantation comorbidity index (HCT-CI)", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Time course of LPI, enhanced labile plasma iron (eLPI), directly chelatable iron (DCI) and hepcidin during allo-SCT", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Association of detectable LPI or eLPI during conditioning and occurrence of elevated liver enzymes during in hospital treatment course for allo-SCT", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Cumulative incidence of graft versus host disease (aGvHD) grade 2-4 with respect to serum ferritin >1000 \u00b5g/l, transfusion burden >20 units of Red blood cells (RBC), LIC >125 \u00b5mol/g, peak value and duration of detectable labile plasma iron above median", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Cumulative incidence of day 100 non-relapse mortality (NRM) with respect to serum ferritin >1000 \u00b5g/l, transfusion burden >20 units of RBC, LIC >125 \u00b5mol/g and peak value and duration of detectable labile plasma iron above median", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Cumulative incidence of infections with respect to serum ferritin >1000 \u00b5g/l, transfusion burden >20 parasitized red blood cell (PRBC), LIC >125 \u00b5mol/g and peak value and duration of detectable labile plasma iron above median", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Median change of serum ferritin and LIC 100 days and 1 year after allo-SCT", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "\u2022 Association between immune profile and iron parameters (serum ferritin >1000 \u00b5g/l, transfusion burden >20 units RBC, LIC >90 \u00b5mol/g and peak value and duration of detectable labile plasma iron above median", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "source": "GWT-TUD GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GWT-TUD GmbH", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2012"
    }
}